uniQure N.V., a gene therapy company, has closed the sale of its global manufacturing facility in Lexington, Massachusetts to Genezen, a contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus (AAV) technologies. “With the completion of the divestiture, we take an important step toward achieving our goal of significantly reducing expenses and streamlining operations,” stated Matt Kapusta, CEO of uniQ...